GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

Abacavir sulfate, lamivudine, and zidovudine (Trizivir), oral tablet

Read renal action and limits
Local official-label summarySource retrieved 2026-11-07See the evidence for this drug2 sources available - open source summaries, references and comparisons

Trizivir / Abacavir sulfate, lamivudine, and zidovudine

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Trizivir - product and source limitations

Use individually selected components if renal adjustment is necessary. Verify all active ingredients.

Before applying: Verify the current prescribing information for this presentation.

Also check: Trizivir - product and source limitations

Official source

Trizivir - labeled renal guidance

Renal action and limits

Abacavir sulfate, lamivudine, and zidovudine (Trizivir), oral tablet
Creatinine clearance (CrCl), mL/min

This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.

Action or finding
The fixed-dose tablet is not recommended at CrCl below 50 mL/min because its components cannot be adjusted independently.
Limits and monitoring
Use individually selected components if renal adjustment is necessary. Verify all active ingredients.
Before use
Verify the current prescribing information for this presentation.

DailyMed SPL version 2, posted Apr 28, 2014 | Selected sections checked 2026-11-07. Independent clinical review pending.

Choose a product and source Trizivir | GlobalRPh RX passage All evidence
Product / population
Abacavir sulfate, lamivudine, and zidovudine (Trizivir), oral tablet
Renal measure
Creatinine clearance (CrCl), mL/min
Source revision
DailyMed SPL version 2, posted Apr 28, 2014
Retrieved
2026-11-07 (not the revision date)
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Renal guidance: 8.6 Patients With Impaired Renal Function

The fixed-dose tablet is not recommended at CrCl below 50 mL/min because its components cannot be adjusted independently. Use individually selected components if renal adjustment is necessary. Verify all active ingredients.

Source revision: DailyMed SPL version 2, posted Apr 28, 2014 | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3354e50f-4dc5-413f-b5ae-87353ab8913d

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Added / rechecked in v7.4

Read source findings

Read source-specific summaries and their qualifications. Retrieval date is not label revision date. Recent review does not imply clinical approval.

Official

Trizivir - labeled renal guidance

Retrieved: 2026-11-07
Source revision: DailyMed SPL version 2, posted Apr 28, 2014

Renal measure: Creatinine clearance (CrCl), mL/min

Read this dated source finding
Rxlist

Trizivir - selected RX renal passage

Retrieved: 2026-11-07
Source revision: Mirror revision not established in the reviewed passage.

Renal measure: Use the renal measure explicitly present in the RX passage.

Read this dated source finding
See all retained evidence sources
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Trizivir - labeled renal guidance

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Abacavir sulfate, lamivudine, and zidovudine (Trizivir), oral tablet

Renal method: Creatinine clearance (CrCl), mL/min
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

Trizivir - selected RX renal passage

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Abacavir sulfate, lamivudine, and zidovudine (Trizivir), oral tablet

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Trizivir - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Trizivir - product and source limitations

Use individually selected components if renal adjustment is necessary. Verify all active ingredients.

How to use this: Verify the current prescribing information for this presentation.

Trizivir - labeled renal guidanceTrizivir - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeTrizivir - labeled renal guidanceTrizivir - selected RX renal passage
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3354e50f-4dc5-413f-b5ae-87353ab8913d

Product identity and scope

Abacavir sulfate, lamivudine, and zidovudine (Trizivir), oral tablet

RDM74-trizivir-identity-1 · Source section: Product identity and scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Trizivir - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Abacavir sulfate, lamivudine, and zidovudine (Trizivir), oral tablet

Renal method: Creatinine clearance (CrCl), mL/min
Source date: DailyMed SPL version 2, posted Apr 28, 2014
Retrieved: 2026-11-07

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8.6 Patients With Impaired Renal Function

The fixed-dose tablet is not recommended at CrCl below 50 mL/min because its components cannot be adjusted independently. Use individually selected components if renal adjustment is necessary. Verify all active ingredients.

RDM74-trizivir-official-1 · Source locator: Renal guidance: 8.6 Patients With Impaired Renal Function

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3354e50f-4dc5-413f-b5ae-87353ab8913d
Retrieved
2026-11-07
Renal-function method
Creatinine clearance (CrCl), mL/min
Source date/version
DailyMed SPL version 2, posted Apr 28, 2014
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
209f98297c1ec26df7aa6d8cadb460b59f320b241d802771d93fbb0d85a49827
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Trizivir - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Abacavir sulfate, lamivudine, and zidovudine (Trizivir), oral tablet

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The fixed-dose tablet is not recommended at CrCl below 50 mL/min because its components cannot be adjusted independently.

RDM74-trizivir-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/trizivir-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
9f12596c2229c09592856afcda7576739bcf05c284da00b0c6062e32c4f61c25

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3354e50f-4dc5-413f-b5ae-87353ab8913d
Source retrieval
2026-11-07. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
f2f0ce63f30072abb97e9c8defd9326debc749c5635049c16d652b1f021e1e9e
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top